Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
160 hedge funds and large institutions have $312M invested in Antares Pharma, Inc. in 2019 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 40 reducing their positions, and 13 closing their positions.
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more capital invested
Capital invested by funds: $204M → $312M (+$108M)
43% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 40
19% more funds holding
Funds holding: 135 → 160 (+25)
57% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $2.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$7.01M |
| 2 |
Millennium Management
New York
|
+$6.95M |
| 3 |
Renaissance Technologies
New York
|
+$4.16M |
| 4 |
Two Sigma Advisers
New York
|
+$3.86M |
| 5 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$3.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$18.8M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.47M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.86M |
| 4 |
SAM
Silvercrest Asset Management
New York
|
-$1.6M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.26M |
ATRS Hedge Fund Activity: Q4 2019 in Review
160 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2019, worth a combined $312M — up 53% from $204M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ATRS positions and 13 closed out — a net gain of 25 holders — while 57 added to existing stakes and 40 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $7.01M. The largest seller was Armistice Capital, exiting entirely with an estimated $18.8M sold.
- 160 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2019, up from 135 in Q3 2019.
- Funds reported $312M of Antares Pharma, Inc. stock for Q4 2019, up 53% quarter-over-quarter.
- 38 funds opened new Antares Pharma, Inc. positions in Q4 2019 and 13 closed out, a net change of +25 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2019 was Two Sigma Investments, an estimated $7.01M added.
- The largest Antares Pharma, Inc. seller in Q4 2019 was Armistice Capital, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2019.